NEW YORK, Jan. 16-Variagenics said today that it has licensed its patents on the methylenetetrahydrofolate reductase gene to GeneOhm Sciences, Sciona, and Tm Bioscience. Variations in the MTHFR gene may be related to thromboembolic disease risk.
The licenses are worldwide and non-exclusive, and give each of the three companies the right to commercialize tests that identify polymorphisms in the gene.
Variagenics retains the right to develop tests relating to other diseases that involve the MTHFR gene.
Yesterday, the company announced a similar dealwith Celera Diagnostics.
GeneOhm, a California startup, is developing a chip-based technology to identify polymorphisms by interruptions in the flow of electrical current.
Sciona is a British diagnostics and pharmacogenomics firm.
Tm Bioscience, based in Toronto, is developing a battery of SNP diagnostic tests.